Sunitinib
Cytostatic · Protein kinase inhibitor
Indications
Treatment of advanced or metastatic renal cell carcinoma. Treatment of unresectable or metastatic gastro-intestinal stromal tumours (GIST). Treatment of unresectable or metastatic pancreatic neuroendocrine tumours.
Dosage
Adults: Treatment of advanced or metastatic renal cell carcinoma. Treatment of unresectable or metastatic gastro-intestinal stromal tumours (GIST): 50 mg daily for 4 wk, followed by a 2 wk treatment-free period to complete 6 wk cycle: adjust dose in steps of 12.5 mg according to tolerability: dose range 25-75 mg/day. Treatment of unresectable or metastatic pancreatic neuroendocrine tumours: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability. Max: 50 mg/day. Children: Not recommended.
Adverse Effects
Pulmonary embolism, haemorrhage, neutropenia, anaemia, thrombocytopenia, leucopenia, lymphopaenia, headache, hypertension, GI upsets, rash, insomnia, skin disorders, alopecia, infections, blood dyscrasias, hypothyroidism, anorexia, dehydration, hypoglycaemia, insomnia, depression, dizziness, dysgeusia, peripheral neuropathy, paraesthesia, hypoaesthesia, hyperaesthesia, lacrimation, oedema, thromboembolism, flushing, hot flush, dyspnoea, cough, pleural effusion, oropharyngeal pain, nasal congestion or dryness, dry mouth, dysphagia, cheilitis, proctalgia, skin, hair and nail discolouration (warn patient), skin and nail disorders, pain (incl chest, musculoskeletal, extremity), muscle spasm and weakness, renal failure, chromaturia, proteinuria, mucosal inflammation, fatigue, fever, chills, flu-like symptoms, wt loss, asthenia, hand-foot syndrome. Decreased haemoglobin and ejection fraction.…
Risk Factor (Pregnancy/Lactation)
Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Contraindications: Severe hepatic impairment. Precautions: Risk of fatal pulmonary haemorrhage, hypertension. Perform complete blood count prior to treatment. Pre-existing cardiac disease, electrolytes disturbances, monitor for thyroid dysfunction, pancreatitis and heart failure. History of, or risk factors for cardiac events or QT prolongation. Diabetes. Perform baseline urinalysis and monitor for development or worsening of proteinuria; discontinue if nephrotic syndrome occurs. Monitor LFTs. Risk of osteonecrosis of the jaw usually associated with concomitant or previous IV bisphosphonate use; perform dental examination and appropriate dental treatment prior to therapy, avoid invasive dental procedures during therapy. Risk of impaired wound healing.
Interactions
Rifampicin, phenobarbital, phenytoin, carbamazepine, dexamethasone, anticoagulants, St John's wort or other CYP3A4 inducers, antifungals, ritonavir, macrolides, grapefruit juice or other CYP3A4 inhibitors, antiarrhythmics or other drugs that prolong QT interval, IV bisphosphonates.
Advice to Patient
Take with or without meals.
Pharmacokinetics
Metabolism: Hepatic. Half-life elimination: Terminal: Sunitinib: 40 to 60 hours; SU12662: 80 to 110 hours. Time to peak, plasma: 6 to 12 hours. Excretion: Feces (61%); urine (16%).
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.